Table 1.
The descriptive statistics of the CMV-seropositive patients under study
| Variables | Subgroup | Frequency (%)/mean ± SD |
|---|---|---|
| Recipient age | - | 32.45 ± 10.82 |
| Missing | 3.0 (2.1) | |
| Donor Age | - | 31.69 ± 11.16 |
| Missing | 39 (26.9) | |
| Recipient gender | Male | 67 (46.2) |
| Female | 78 (53.8) | |
| Missing | 0 (0.0) | |
| Donor gender | Male | 82 (56.6) |
| Female | 57 (39.3) | |
| Missing | 6 (4.1) | |
| Diagnosed disease | NHL | 11 (7.6) |
| HD | 10 (6.9) | |
| AML | 75 (51.7) | |
| ALL | 35 (24.1) | |
| Aplastic Anemia | 6 (4.1) | |
| Other | 4 (2.8) | |
| Missing | 4 (2.8) | |
| GVHD | Yes | 65 (44.8) |
| No | 75 (51.7) | |
| Missing | 5 (3.4) | |
| Conditioning regimen | MAC1 | 77 (53.1) |
| MAC2 | 32 (22.1) | |
| MAC3 | 14 (9.7) | |
| RIC | 17 (11.7) | |
| AA-AF | 5 (3.4) | |
| Missing | 0 (0.0) | |
| GVHD prophylaxis | CSA+MTX | 89 (61.4) |
| CSA+MTX+ATG | 15 (10.3) | |
| Unclassified | 41 (28.3) | |
| CMV IgG | Positive | 145 (72.1) |
| Negative | 21 (10.4) | |
| Missing | 35 (17,4) | |
| CMV reactivation | Positive | 12 (8.3) |
| Negative | 133 (91.7) | |
| Missing | 0 (0) |